Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman Sells 21,375 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 21,375 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.66, for a total value of $227,857.50. Following the completion of the transaction, the chief financial officer now directly owns 243,054 shares of the company’s stock, valued at approximately $2,590,955.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Robert Thomas Freeman also recently made the following trade(s):

• On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.00, for a total value of $174,000.00.
• On Wednesday, September 11th, Robert Thomas Freeman sold 8,561 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.01, for a total value of $85,695.61.
• On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total transaction of $16,500.00.
• On Friday, July 19th, Robert Thomas Freeman sold 38,858 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.01, for a total transaction of $388,968.58.
• On Wednesday, July 17th, Robert Thomas Freeman sold 22,100 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.00, for a total transaction of $221,000.00.

Alignment Healthcare Stock Performance

Shares of ALHC stock opened at $10.92 on Friday. The company has a fifty day moving average price of $9.77 and a two-hundred day moving average price of $7.88. Alignment Healthcare, Inc. has a one year low of $4.46 and a one year high of $12.36. The stock has a market cap of $2.09 billion, a P/E ratio of -13.00 and a beta of 1.47. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.61 and a quick ratio of 1.61.

Alignment Healthcare (NASDAQ:ALHC) last issued its earnings results on Thursday, August 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The business had revenue of $681.29 million during the quarter, compared to the consensus estimate of $637.66 million. Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. Alignment Healthcare’s revenue was up 47.3% on a year-over-year basis. During the same period last year, the business posted ($0.15) EPS. As a group, equities analysts predict that Alignment Healthcare, Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Alignment Healthcare

A number of large investors have recently added to or reduced their stakes in ALHC. Jacobs Levy Equity Management Inc. acquired a new position in shares of Alignment Healthcare in the first quarter valued at $918,000. Vanguard Group Inc. grew its stake in Alignment Healthcare by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after buying an additional 93,262 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in Alignment Healthcare by 31.8% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company’s stock valued at $85,250,000 after acquiring an additional 2,630,788 shares during the period. Bank of New York Mellon Corp lifted its position in Alignment Healthcare by 27.5% during the second quarter. Bank of New York Mellon Corp now owns 382,462 shares of the company’s stock worth $2,991,000 after acquiring an additional 82,559 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of Alignment Healthcare during the first quarter worth approximately $57,000. Institutional investors own 86.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ALHC shares. TD Cowen boosted their price target on Alignment Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Piper Sandler restated an “overweight” rating and issued a $10.00 target price (up previously from $8.00) on shares of Alignment Healthcare in a research note on Tuesday, August 6th. Robert W. Baird raised their price target on shares of Alignment Healthcare from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th. Stifel Nicolaus boosted their price objective on shares of Alignment Healthcare from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Barclays raised their target price on shares of Alignment Healthcare from $4.50 to $7.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.83.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.